^
    Back
    Association details:
    Biomarker:KMT2D underexpression
    Cancer:Chronic Myeloid Leukemia
    Drug:imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Cancer Cell Int
    Title:

    MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia

    Excerpt:
    Here we investigated the expression profile of both genes in CML patients in different stages of the disease, in patients showing different responses to therapy with IM...MLL2/KMT2D was decreased in patients resistant to IM treatment...
    DOI:
    10.1186/s12935-018-0523-1